Featured Research

from universities, journals, and other organizations

Stents linked to low major adverse coronary events

Date:
October 30, 2013
Source:
Cardiovascular Research Foundation
Summary:
A new study found that both drug-eluting stents (DES) with biocompatible polymers and DES with biodegradable polymers were associated with low major adverse coronary events, demonstrating the non-inferiority of the biocompatible polymer stents in patients undergoing percutaneous coronary intervention.

A new study found that both drug-eluting stents (DES) with biocompatible polymers and DES with biodegradable polymers were associated with low major adverse coronary events, demonstrating the non-inferiority of the biocompatible polymer stents in patients undergoing percutaneous coronary intervention (PCI). The findings of the SORT-OUT VI trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Compared with bare metal stents, first generation DES reduced the risk of restenosis. However, the risk of stent thrombosis was a concern and newer generation DES have been designed to improve efficacy, safety, and device performance. To date, there are no large scale randomized comparison studies of biodegradable polymer-coated stents and biocompatible polymer-coated stents in all-comer populations. The SORT-OUT VI trial investigated the safety and efficacy of a durable but biocompatible polymer coated zotarolimus-eluting stent compared with a biodegradable polymer-coated biolimus-eluting stent in a population-based setting.

SORT-OUT VI was a multicenter, all-comer, non-inferiority trial that randomized 2,999 patients with stable coronary artery disease or acute coronary syndromes. The trial was performed within the framework of the Scandinavian Organization for Randomized Trials with Clinical Outcomes, and used patient-driven clinical event detection through Danish health care registries.

Patients were randomized to receive either a zotarolimus-eluting permanent polymer stent (n=1,502) or a biolimus-eluting biodegradable stent (n=1,497). The primary endpoint was a composite of major adverse cardiac events including cardiac death, myocardial infarction, and target lesion revascularization after 12 months.

After 12 months the percentage of patients with major adverse cardiac events was similarly low in both the zotarolimus-eluting and biolimus-eluting stent groups (5.3 percent and 5.1 percent, respectively), demonstrating the non-inferiority of the zotarolimus-eluting stent.

"The SORT OUT VI trial found that both zotarolimus-eluting and the biolimus-eluting stents were associated with low major adverse cardiac events," said lead investigator Bent Raungaard MD. Dr. Raungaard is Chief Physician and Associate Professor at Aalborg University Hospital in Denmark.

"Further, the zotarolimus-eluting stent was found to be non-inferior to the biolimus-eluting stent for patients treated with PCI."


Story Source:

The above story is based on materials provided by Cardiovascular Research Foundation. Note: Materials may be edited for content and length.


Cite This Page:

Cardiovascular Research Foundation. "Stents linked to low major adverse coronary events." ScienceDaily. ScienceDaily, 30 October 2013. <www.sciencedaily.com/releases/2013/10/131030093218.htm>.
Cardiovascular Research Foundation. (2013, October 30). Stents linked to low major adverse coronary events. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/2013/10/131030093218.htm
Cardiovascular Research Foundation. "Stents linked to low major adverse coronary events." ScienceDaily. www.sciencedaily.com/releases/2013/10/131030093218.htm (accessed September 2, 2014).

Share This




More Health & Medicine News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Doctors Fear They're Losing Battle Against Ebola

Doctors Fear They're Losing Battle Against Ebola

AP (Sep. 2, 2014) As a third American missionary is confirmed to have contracted Ebola in Liberia, doctors on the ground in West Africa fear they're losing the battle against the outbreak. (Sept. 2) Video provided by AP
Powered by NewsLook.com
Tech Giants Bet on 3D Headsets for Gaming, Healthcare

Tech Giants Bet on 3D Headsets for Gaming, Healthcare

AFP (Sep. 2, 2014) When Facebook acquired the virtual reality hardware developer Oculus VR in March for $2 billion, CEO Mark Zuckerberg hailed the firm's technology as "a new communication platform." Duration: 02:24 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins